
The EU QPPV carries the central accountability for a marketing authorisation holder’s safety system, but Greece also expects a local pharmacovigilance contact. Companies that treat[…]

Adverse reactions are now described on company websites, patient forums and social platforms long before they reach a safety department. EU good pharmacovigilance practice makes[…]

For biological medicines, the safety of a case often depends on which product and which batch the patient received. EU pharmacovigilance guidance therefore asks for[…]

Vaccines are given to large, healthy populations, often in campaigns, so coincidental events are reported in volume. EMA’s GVP guidance on vaccines asks marketing authorisation[…]

The benefit-risk evaluation is the part of a periodic report where a company states its view of the product. ICH E2C(R2) asks for it to[…]

EudraVigilance is the EU system for collecting and analysing suspected adverse reaction reports, and EVDAS is the tool through which marketing authorisation holders (MAHs) can[…]

Under the EU Clinical Trials Regulation, sponsors report suspected unexpected serious adverse reactions (SUSARs) straight to EudraVigilance, on fixed clocks that start when the sponsor[…]

The Development Safety Update Report (DSUR) is the annual safety review that sponsors prepare while a medicine is still in development. Under ICH E2F it[…]

Pregnancy reports are among the most demanding cases in pharmacovigilance. The event may only appear months after the report, the outcome may be normal, and[…]

When a product is licensed, co-marketed, distributed or manufactured under contract, safety information has to travel between companies without delay or loss. The safety data[…]